Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/crionm/volume-2017/8241624/figures/8241624.fig.001a.svgz" name="8241624.fig.001a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Demonstrating the first patient’s (55-year-old male) response with initial imaging and final image</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/crionm/volume-2017/8241624/figures/8241624.fig.001b.svgz" name="8241624.fig.001b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Demonstrating the second patient’s (79-year-old male) response with initial imaging and final image</td></tr></table>

Case Reports in Oncological Medicine

fig1

Figure 1

Figure 1: Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma 